How Can Transvaginal Lawsuits Impact Boston Scientific’s Future Earnings?

-7.01%
Downside
68.49
Market
63.69
Trefis
BSX: Boston Scientific logo
BSX
Boston Scientific

Boston Scientific recently added a new safety warning for its surgical mesh devices, which are used to repair pelvic mesh disorders in women. With more than 300,000 women undergoing transvaginal surgeries each year since 2010, the market for these devices has grown considerably, inviting more companies to enter the lucrative market. However, transvaginal mesh is one of the most litigated products, as thousands of lawsuits have been filed by women for mesh-related injuries against the manufacturers. Further, the transvaginal mesh law suit could be the largest in terms of the amount required to settle the charges. This seems quite evident as medical device companies such as Boston Scientific had more than 30,000 pending cases linked to transvaginal mesh complications against it by November 2015.

Relevant Articles
  1. Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
  2. What’s Next For Boston Scientific Stock After 5% Gains In A Week?
  3. Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
  4. Which Is A Better Buy – Boston Scientific Stock Or Abbott?
  5. What’s Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
  6. New Product Launches To Aid Boston Scientific’s Q1

Below we analyse the potential impact of these lawsuits on Boston Scientific’s future earnings:

Transvaginal Mesh Lawsuits_5

When we look at the combined impact of litigation charges to settle mesh related lawsuits and the loss from decline in sales of this product, the total loss that Boston Scientific might have to incur in the future might surpass $2 billion.

View Interactive Institutional Research (Powered by Trefis):

Global Large Cap U.S. Mid & Small Cap European Large & Mid Cap
More Trefis Research